BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 17229796)

  • 1. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.
    Vermeire S; Noman M; Van Assche G; Baert F; D'Haens G; Rutgeerts P
    Gut; 2007 Sep; 56(9):1226-31. PubMed ID: 17229796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
    Sokol H; Seksik P; Carrat F; Nion-Larmurier I; Vienne A; Beaugerie L; Cosnes J
    Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial.
    Van Assche G; Magdelaine-Beuzelin C; D'Haens G; Baert F; Noman M; Vermeire S; Ternant D; Watier H; Paintaud G; Rutgeerts P
    Gastroenterology; 2008 Jun; 134(7):1861-8. PubMed ID: 18440315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
    Baert F; Noman M; Vermeire S; Van Assche G; D' Haens G; Carbonez A; Rutgeerts P
    N Engl J Med; 2003 Feb; 348(7):601-8. PubMed ID: 12584368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial.
    Farrell RJ; Alsahli M; Jeen YT; Falchuk KR; Peppercorn MA; Michetti P
    Gastroenterology; 2003 Apr; 124(4):917-24. PubMed ID: 12671888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximab.
    Mantzaris GJ; Viazis N; Petraki K; Papamichael K; Theodoropoulos I; Roussos A; Karakoidas C; Koilakou S; Raptis N; Smyrnidis A; Agalos G; Karamanolis DG
    Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1042-8. PubMed ID: 20139856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.
    Schnitzler F; Fidder H; Ferrante M; Noman M; Arijs I; Van Assche G; Hoffman I; Van Steen K; Vermeire S; Rutgeerts P
    Gut; 2009 Apr; 58(4):492-500. PubMed ID: 18832518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody response to infliximab and its impact on pharmacokinetics can be transient.
    Vande Casteele N; Gils A; Singh S; Ohrmund L; Hauenstein S; Rutgeerts P; Vermeire S
    Am J Gastroenterol; 2013 Jun; 108(6):962-71. PubMed ID: 23419382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.
    Hoekman DR; Brandse JF; de Meij TG; Hummel TZ; Löwenberg M; Benninga MA; D'Haens GR; Kindermann A
    Scand J Gastroenterol; 2015; 50(9):1110-7. PubMed ID: 25865965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Less Anti-infliximab Antibody Formation in Paediatric Crohn Patients on Concomitant Immunomodulators.
    Kansen HM; van Rheenen PF; Houwen RHJ; Tjon A Ten W; Damen GM; Kindermann A; Escher JC; Wolters VM;
    J Pediatr Gastroenterol Nutr; 2017 Oct; 65(4):425-429. PubMed ID: 28945207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of efficacy, pharmacokinetics, and immunogenicity between infliximab mono- versus combination therapy in ulcerative colitis.
    Hayes MJ; Stein AC; Sakuraba A
    J Gastroenterol Hepatol; 2014 Jun; 29(6):1177-85. PubMed ID: 24955449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab.
    Plasencia C; Pascual-Salcedo D; Nuño L; Bonilla G; Villalba A; Peiteado D; Díez J; Nagore D; del Agua AR; Moral R; Martin-Mola E; Balsa A
    Ann Rheum Dis; 2012 Dec; 71(12):1955-60. PubMed ID: 22563028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of concomitant endoscopic balloon dilation for intestinal stricture during long-term infliximab therapy in patients with Crohn's disease.
    Ono Y; Hirai F; Matsui T; Beppu T; Yano Y; Takatsu N; Takaki Y; Nagahama T; Hisabe T; Yao K; Higashi D; Futami K
    Dig Endosc; 2012 Nov; 24(6):432-8. PubMed ID: 23078435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum infliximab concentrations in pediatric inflammatory bowel disease.
    Hämäläinen A; Sipponen T; Kolho KL
    Scand J Gastroenterol; 2013 Jan; 48(1):35-41. PubMed ID: 23148710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions.
    Kinney T; Rawlins M; Kozarek R; France R; Patterson D
    Am J Gastroenterol; 2003 Mar; 98(3):608-12. PubMed ID: 12650795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methotrexate polyglutamation in relation to infliximab pharmacokinetics in rheumatoid arthritis.
    Dervieux T; Weinblatt ME; Kivitz A; Kremer JM
    Ann Rheum Dis; 2013 Jun; 72(6):908-10. PubMed ID: 23161901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn's disease.
    Oh EH; Ko DH; Seo H; Chang K; Kim GU; Song EM; Seo M; Lee HS; Hwang SW; Yang DH; Ye BD; Byeon JS; Myung SJ; Yang SK; Park SH
    World J Gastroenterol; 2017 Feb; 23(8):1489-1496. PubMed ID: 28293096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn's Disease.
    Gomes LEM; da Silva FAR; Pascoal LB; Ricci RL; Nogueira G; Camargo MG; Lourdes Setsuko Ayrizono M; Fagundes JJ; Leal RF
    Clinics (Sao Paulo); 2019 Apr; 74():e824. PubMed ID: 30994711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease.
    Imaeda H; Andoh A; Fujiyama Y
    J Gastroenterol; 2012 Feb; 47(2):136-43. PubMed ID: 21953314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.